Compare · ABSI vs INCY
ABSI vs INCY
Side-by-side comparison of Absci Corporation (ABSI) and Incyte Corp. (INCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and INCY operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $26.29B, about 15.9x ABSI ($1.65B).
- INCY has been more active in the news (8 items in the past 4 weeks vs 6 for ABSI).
- INCY has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- Incyte Corp.
- Price
- -
- -
- Market cap
- $1.65B
- $26.29B
- 1M return
- -
- +9.11%
- 1Y return
- -
- +54.42%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest ABSI
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- SEC Form 4 filed by CMO, Head of R&D Somaratne Ransi Mudalinayake
- SEC Form 3 filed by new insider Somaratne Ransi Mudalinayake
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
Latest INCY
- President, Global Head of R&D Cagnoni Pablo J sold $1,356,174 worth of shares (10,801 units at $125.56), decreasing direct ownership by 6% to 183,200 units (SEC Form 4)
- Canaccord Genuity initiated coverage on Incyte with a new price target
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- President, Global Head of R&D Cagnoni Pablo J sold $1,305,422 worth of shares (10,640 units at $122.69), decreasing direct ownership by 5% to 204,804 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A exercised 2,207 shares at a strike of $106.47 and sold $273,646 worth of shares (2,207 units at $123.99) (SEC Form 4)
- President, Global Head of R&D Cagnoni Pablo J sold $1,901,794 worth of shares (15,888 units at $119.70), decreasing direct ownership by 7% to 215,444 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A exercised 45,767 shares at a strike of $78.48 and sold $5,734,376 worth of shares (47,954 units at $119.58), decreasing direct ownership by 3% to 61,441 units (SEC Form 4)
- New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
- Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
- SEC Form 10-Q filed by Incyte Corp.